Foghorn Therapeutics Inc. — Form 8-K Summary
Reporting date: June 14, 2021; filed June 15, 2021. The filing reports a financing amendment and furnishes an investor presentation. Foghorn is a biotechnology company; this 8-K does not provide quarterly or annual financial results.
Material Financing Amendment
- Foghorn and Oxford Finance LLC entered into a First Amendment to the November 19, 2020 Loan and Security Agreement.
- The amendment extends or otherwise modifies the definition of the “Second Draw Period” to run from the applicable commencement date until the earlier of August 31, 2021 or the occurrence of an event of default.
- In consideration, Foghorn agreed to pay the collateral agent an amendment fee of $15,000.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt balances, cash balances, liquidity runway, or other operating metrics. It indicates the existence of a loan facility with Oxford Finance but does not state the facility’s total commitment, outstanding balance, interest rate, maturity, or remaining borrowing capacity.
Guidance, Outlook, Risks, and Unusual Items
- The company furnished an investor presentation dated June 15, 2021 for its Virtual R&D Day and future investor meetings; the presentation’s contents are not included in the provided filing text.
- The amended borrowing window ends on August 31, 2021 unless an event of default occurs earlier, creating a time-limited financing availability condition.
- The amendment fee is an unusual financing-related cash cost disclosed in this filing.
- No financial guidance, clinical-development guidance, risk update, contingency disclosure, or management commentary is provided in the filing text beyond the financing amendment and reference to the investor presentation.
Investor Verification Items
- Review Exhibit 10.1 for the complete amended borrowing conditions, covenants, collateral provisions, fees, events of default, and outstanding obligations.
- Confirm whether Foghorn drew additional funds before the August 31, 2021 end of the Second Draw Period and determine the resulting debt balance and liquidity runway.
- Review Exhibit 99.1 for the company’s R&D pipeline, clinical timelines, development priorities, and any guidance or forward-looking statements.
- Assess subsequent filings for changes to the Oxford facility, additional financing, defaults, or amendments.